While EGFR‐TKIs significantly improve the survival and quality of life in advanced NSCLC patients carrying EGFR mutations, acquired resistance to these inhibitors limits their clinical benefit, thus creating challenges for treatment and management. This evidence concerns the gene EGFR and non-small cell lung carcinoma.